The primary objective of the study is to evaluate the PK of AMG 510 administered in the fasted and fed state in healthy participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
14
Oral Tablet
Covance Clinical Research Unit, Inc
Daytona Beach, Florida, United States
Maximum Plasma Concentration (Cmax) of AMG 510
Time frame: Day 1 and Day 4
Area Under the Plasma Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 510
Time frame: Day 1 and Day 4
Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of AMG 510
Time frame: Day 1 and Day 4
Number of Participants with an Adverse Event (AE)
Any clinically significant changes in clinical laboratory tests, 12-lead electrocardiograms and vital signs will be recorded as AEs.
Time frame: Day 1 to Day 6
Cmax of AMG 510 Metabolite M24
Time frame: Day 1 and Day 4
AUClast of AMG 510 Metabolite M24
Time frame: Day 1 and Day 4
AUCinf of AMG 510 Metabolite M24
Time frame: Day 1 and Day 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.